The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS : the Pilot Study of a Clinical Trial
COVID-19 pandemic has created a global health challenge. Many pharmaceuticals have been repurposed as potential treatments, though many have not been promising. Due to the inflammatory and destructive effects of the virus on alveolar cells, the effect of exogenous surfactant was assessed as a potential treatment of lung dysfunction in COVID-19 patients. In this pilot study of the clinical trial, 49 patients aged 35-80 years with COVID-19 admitted in ICU entered the study (22 patients intubated and 23 had face masks; 4 patients in the control arm). The treatment arm patients received two consecutive doses of surfactant. P/F ratio (based on serial blood gas analyses before and 12 hours after 2 doses of surfactant) and also, clinical outcomes were assessed.in COVID-19 adult patients, surfactant significantly improved pulmonary P/F ratio both in intubated and face mask COVID-19 patients (increasing from 119.2 ± 51.7 to 179.4 ± 115.5). The rate of extubation was much better than similar country-wide studies. Surfactant significantly alleviates the respiratory status in moderate to severe COVID-19 ARDS with two consecutive 100 mg doses of surfactant (with 6 hours' interval) though previous studies have been controversial, regarding the effect of surfactant in general forms of ARDS. Higher doses might have better effects, mandating more trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Iranian journal of pharmaceutical research : IJPR - 20(2021), 3 vom: 09., Seite 553-559 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fani, Kamal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.12.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.22037/ijpr.2021.115390.15347 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33440469X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33440469X | ||
| 003 | DE-627 | ||
| 005 | 20231225223632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22037/ijpr.2021.115390.15347 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM33440469X | ||
| 035 | |a (NLM)34904008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fani, Kamal |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS |b the Pilot Study of a Clinical Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a COVID-19 pandemic has created a global health challenge. Many pharmaceuticals have been repurposed as potential treatments, though many have not been promising. Due to the inflammatory and destructive effects of the virus on alveolar cells, the effect of exogenous surfactant was assessed as a potential treatment of lung dysfunction in COVID-19 patients. In this pilot study of the clinical trial, 49 patients aged 35-80 years with COVID-19 admitted in ICU entered the study (22 patients intubated and 23 had face masks; 4 patients in the control arm). The treatment arm patients received two consecutive doses of surfactant. P/F ratio (based on serial blood gas analyses before and 12 hours after 2 doses of surfactant) and also, clinical outcomes were assessed.in COVID-19 adult patients, surfactant significantly improved pulmonary P/F ratio both in intubated and face mask COVID-19 patients (increasing from 119.2 ± 51.7 to 179.4 ± 115.5). The rate of extubation was much better than similar country-wide studies. Surfactant significantly alleviates the respiratory status in moderate to severe COVID-19 ARDS with two consecutive 100 mg doses of surfactant (with 6 hours' interval) though previous studies have been controversial, regarding the effect of surfactant in general forms of ARDS. Higher doses might have better effects, mandating more trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Pulmonary involvement | |
| 650 | 4 | |a Surfactant | |
| 700 | 1 | |a Ghahremani, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Fathi, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Massoudi, Nilofar |e verfasserin |4 aut | |
| 700 | 1 | |a Tavana, Sasan |e verfasserin |4 aut | |
| 700 | 1 | |a Nooraee, Navid |e verfasserin |4 aut | |
| 700 | 1 | |a Malekpour Alamdari, Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Besharat, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi Abrandabadi, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Pirsalehi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Khabiri Khatiri, Mohammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Amini Pouya, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Rajaei, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Dabbagh, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Iranian journal of pharmaceutical research : IJPR |d 2010 |g 20(2021), 3 vom: 09., Seite 553-559 |w (DE-627)NLM232822573 |x 1726-6890 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:3 |g day:09 |g pages:553-559 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.22037/ijpr.2021.115390.15347 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 3 |b 09 |h 553-559 | ||